Parminder K. Judge, PhD, explains why eGFR and electrolytes should be monitored when diuretics are added to reach intensive BP targets in patients with CKD
|Videos|November 28, 2014
Pharmacy Times Asks a Burmans Pharmacist: What Are Your Wellness Initiatives?
Vince Canzanese, RPh, director of compounding at Burmans Pharmacy in Brookhaven, Pennsylvania, discusses the independent pharmacy's wellness initiatives.
Advertisement
Vince Canzanese, RPh, director of compounding at
“At Burmans, we’ve championed a lot of health initiatives,” he says. “One of our biggest ones is weight management or diabetes management for patients. That centers around compliance and health attitudes.”
Advertisement
Related to this article
The once-nightly drop, previously approved to reverse pupil dilation, met its primary end point in 2 phase 3 trials, with conjunctival hyperemia most common.
Isatuximab on-body injector enables quick, hyaluronidase-free subcutaneous dosing, reducing reactions and easing multiple myeloma clinic workflows.
A summer PCAC vote pushes 6 peptide families toward the 503A bulks list—but the FDA's decision is still pending.
The project maps how flu and HIV proteins enter cells, with the aim of developing longer-lasting vaccines.
VAX-31 met all primary end points against PCV20 and PCV21 in the pivotal phase 3 OPUS-1 trial.
Pharmacy teams can prevent early discontinuation by setting clear expectations for when—and how—a medication's benefit will become apparent.
The once-daily device, bioequivalent to the existing prefilled syringe, gives adults with AChR antibody-positive generalized MG a second self-injection option.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Peptide Compounding Is Evolving: What Pharmacists Need to Know Now
2
Dostarlimab Receives FDA Accelerated Approval for MSI-H/dMMR Locally Advanced Rectal Cancer
3
FDA Approves Phentolamine Eye Drop for Presbyopia in Adults
4
VAX-31 Meets All Primary End Points vs PCV20 and PCV21 in Pivotal Phase 3 OPUS-1 Trial
5